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Background: Maintenance therapy with gefitinib notably improves survival in patients with advanced non-small
cell lung cancer (NSCLC) and EGFR mutation-positive tumors, but the economic impact of this practice is unclear.
Methods: A decision-analytic model was developed to simulate 21-day patient transitions in a 10-year time
horizon. The clinical data were primarily obtained from the results of a pivotal phase III trial that assessed gefitinib
maintenance treatment in patients with advanced NSCLC. The cost data were derived from the perspective of the
Chinese health care system. The primary outcome was the incremental cost-effectiveness ratio (ICER) at a
willingness-to-pay (WTP) threshold of 3 times the per capita GDP of China. Sensitivity analyses were used to explore
the impact of uncertainty regarding the results. The impact of the gefitinib patient assistance program (GPAP) was
evaluated.
Results: After EGFR genotyping, gefitinib maintenance treatment for advanced NSCLC with EGFR mutations
increased the life expectancy by 0.74 years and 0.46 QALYs compared with routine follow-up at an additional cost
of $26,149.90 USD ($7,178.20 with the GPAP). The ICER for gefitinib maintenance was $57,066.40 and $15,664.80 per
QALY gained (at a 3% discount rate) without and with the GPAP, respectively. The utility of progression free
survival, the hazard ratio of progression-free survival for gefitinib treatment and the cost of gefitinib per dose were
the three factors that had the greatest influence on the results.
Conclusions: These results indicate that gene-guided maintenance therapy with gefitinib with the GPAP might be
a cost-effective treatment option.
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Lung cancer is the most prevalent malignant cancer in
adults, with over 1.3 million deaths from the disease per
year [1]. Non-small cell lung cancer (NSCLC) accounts
for nearly 85% of all cases of lung cancer [2]. Locally
advanced or metastatic NSCLC accounts for approxi-
mately 46% of cases at the time of presentation [3]. The
current treatment guidelines recommend four to six* Correspondence: wbwithtg@hotmail.com
6Medical Decision and Economic Group, Department of Pharmacy, Renji
Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University,
Dongfang Road 1630, Shanghai, China
Full list of author information is available at the end of the article
© 2013 Zhu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcycles of first-line platinum-based doublet chemo-
therapy for advanced NSCLC [4]. However, the median
overall survival (OS) time is still approximately 10
months, and even in the most favorable situations, most
patients die within two years. Clearly, the poor clinical
outcomes of advanced NSCLC present a challenge for
oncologists to improve the clinical benefits of new treat-
ment for patients before disease progression.
The role of maintenance therapy in patients who
remained progression free after first-line chemotherapy
has been well established by several Phase III trials
[5-11]. At present, pemetrexed and erlotinib have been
approved for the maintenance treatment of advanced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhu et al. BMC Cancer 2013, 13:39 Page 2 of 11
http://www.biomedcentral.com/1471-2407/13/39NSCLC in Europe and the USA [12]. Although gefitinib,
an EGFR tyrosine kinase inhibitor (TKI), failed to show
a significant survival benefit with the addition of gefiti-
nib to platinum-based chemotherapy [13,14]. However,
it has been recommended as a first-line regimen for
treating advanced NSCLC with EGFR mutations due to
its more favorable health outcomes compared with
platinum-based chemotherapy [15,16]. In patients with
pretreated advanced NSCLC, gefitinib showed the
noninferiority in comparison with docetaxel for overall
survival [17]. One recent phase III clinical study exam-
ined gefitinib as a maintenance therapy in patients who
attained tumor control with first-line chemotherapy
[11]. Li Z. and colleagues found that progression-free
survival (PFS) was significantly longer with gefitinib
than with placebo. In patients with tumors bearing an
EGFR mutation, the median PFS reached 16.6 months
(HR 0.17, 95% CI 0.07–0.42). By contrast, PFS was not
significantly different between the gefitinib and control
arms for patients with EGFR mutation-negative tumors
(HR 0.86, 0.48–1.51). This comes at a cost of substan-
tially higher drug expenses due to the high price of gefi-
tinib. Limiting this treatment to patients with EGFR
mutation-positive tumors might be one potential way to
improve the economic outcome of gefitinib mainten-
ance treatment.
Health resource allocation decisions are based increas-
ingly on economic analyses that identify the therapies that
provide the greatest health benefits at acceptable costs,
especially in a health resource-limited setting. Because
clinical trials rarely include economic health assessments,
mathematical modeling is widely used to perform eco-
nomic health analyses, particularly for extrapolating to
timepoints beyond trial durations. The objective of our
study was to compare the economic outcome of gene-
guided gefitinib maintenance treatment with the routine
follow-up following first-line platinum-based chemother-
apy for advanced NSCLC with EGFR mutation from the
perspective of the Chinese health care system. Although
erlotinib and pemetrexed have been used for maintenance
treatment, the current analysis would not include otherEGFR genotyping
Routine follow-up
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(Routine follow-up)
M
M
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Figure 1 The schematics of the decision tree (A) and the Markov stattreatment arms due to no clinical trials for directly com-
paring the clinical outcomes of gefitinib, erlotinib and
pemetrexed.
Methods
Analytical overview and model structure
An economic model was constructed to analyze the ten-
year clinical and economic outcomes of gefitinib main-
tenance therapies for patients with advanced NSCLC.
Patients were assumed to either initiate observation
with routine follow-up or to initiate maintenance treat-
ment with gefitinib if the EGFR mutation screening was
positive (Figure 1A). Health outcomes and costs were
modeled using a Markov cohort model (Figure 1B) with
four health states: progression free survival, progressed
survival with supportive care, progressed survival with
2nd-line chemotherapy and death. In Markov models, a
patient is always in one of a series of distinguished
health states, called Markov states. All events are repre-
sented as movements from one state to another [18,19].
The cycle length of the model was 3 weeks. The risk of
PFS and OS for patients in the model was determined
according to the FS and OS survival data reported in
clinical trials [11,20]. The R statistical environment
(version 2.15.0; R Development Core Team, Vienna,
Austria) was used to develop and solve the model. This
economic study was based on a literature review and
model techniques, and did not require approval by the
institutional Research Ethics Board.
We assumed that the clinical characteristics of the
hypothetical cohort were similar to those reported by
Zhang L. et al. [11] All patients with histologically or
cytologically confirmed stage IIIb or IV NSCLC had
completed four cycles of first-line platinum-based doub-
let chemotherapy, and they exhibited no disease pro-
gression or unacceptable toxic effects. They were 18
years or older and the WHO performance status was 0–
2. Except the four cycles of first-line platinum-based
doublet chemotherapy, no other therapeutic agent was
previously administered. The initial health status of the
patients was progression free. Two competing strategiesProgression free
Progressed
(BSC)
Death
Progressed
(Chemotherapy)
e transition model (B).
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for all patients (Control strategy) and 2) routine follow-
up plus gefitinib maintenance for patients with EGFR
mutation-positive tumors and routine follow-up only for
patients with EGFR mutation-negative tumors (Gefitinib
strategy). After the cancer progressed, patients were
treated with 2nd-line chemotherapy or supportive care.
To simplify the model, we assumed there is no possible
to go from “progressed” back to “disease free” upon
treatment [21,22].
The analysis was conducted from the perspective of
the Chinese healthcare system. The costs are presented
in 2012 US dollars. The outcomes calculated for each
strategy included progression free life years, overall life
years (LYs), quality-adjusted life years (QALYs) and the
costs of advanced NSCLC care. The results are
reported as the incremental cost-effective ratio (ICER)
over the 10-year period calculated using the model.
The costs and QALYs were each discounted at an
annual rate of 3%.
Clinical data and adjusted indirect comparisons
The transition parameters and proportions were based
on a meta-analysis or randomized clinical trials to the
greatest possible extent.
Kaplan-Meier survival curves for PFS for each strategy
were taken from the pivotal gefitinib maintenance clin-
ical trials [11]. A total of 296 patients with advanced
NSCLC without disease progression after first-line
chemotherapy were enrolled in this trial and randomly
assigned 1:1 to receive either the Gefitinib strategy or
the Control strategy. In this report, nearly 50% of
patients tested were deemed EGFR mutation-positive;
27% of the study population had tumor samples avail-
able for EGFR mutation analysis. The survival analysis
demonstrated that the median PFS for patients with
EGFR mutation-positive tumors was significantly longer
in the gefitinib maintenance arm than in the control
arm (16.6 vs. 2.8 months, respectively, p < 0.001). The
hazard ratio (HR) of PFS for gefitinib maintenance
against the control arm for patients with EGFR
mutation-positive tumors was 0.17 (95% CI: 0.07–0.42),
but the EGFR mutation-negative subgroups did not
differ significantly. The incidence of adverse events was
similar between the two arms (p > 0.05). The cumulative
probabilities of serious adverse events (SAEs, grade
3–4) in the gefitinib maintenance and control arms were
7% and 3%, respectively.
After disease progressed, patients would receive either
2nd-line chemotherapy or supportive care. The propor-
tion of patients receiving 2nd-line chemotherapy was
derived from literatures [5-10]. Kaplan-Meier overall
survival (OS) curves for 2nd-line chemotherapy and
supportive care were obtained from the trial reported byShepherd FA and colleagues [20]. The median OS
periods were 7.5 and 4.6 months in the 2nd-line chemo-
therapy and control arms, respectively. Weibull curves
were fitted to the data extracted from the Kaplan-Meier
curves using R statistical software because the Weibull
distribution provided better fits to survival data than
did other models [23-25]. The estimated scale and shape
parameters, standard errors (SEs), adjusted R2 and cor-
relation coefficients are presented in Table 1. The shape
parameter (γ) allows the hazard function to increase or
decrease with increasing time; if γ > 1.0, the hazard rate
strictly increases in a nonlinear pattern with increasing
time. The scale parameter (λ) is related to the unit of time
measurement. The survival probability at time t could be
calculated by following formula: S(t) = P(T ≥ t) = exp(−λtγ).
The transition probability at current cycel t could be
calculated by following formula:
P tð Þ ¼ 1 exp λ t  1ð Þγ  λtγ½ 
Cost and utility
The costs were estimated from the perspective of the
Chinese health care system. Indirect costs were not
included in this analysis. The direct medical costs
considered in the model were: the detection of EGFR
mutation, maintenance and 2nd-line chemotherapy
(including prescription, preparation, and administra-
tion), concomitant medication during therapy, man-
aging treatment-related SAEs, routine follow-up and
laboratory tests.
The cost of EGFR genotyping per patient was provided
by the AstraZeneca Innovation Centre China, Shanghai
laboratory. The estimated treatment costs were based on
the following schedules: gefitinib (250 mg per day) would
be administered to patients with progression free survival
after initial chemotherapy until the disease progressed.
After the cancer progressed, 2nd-line chemotherapy and
supportive care would be available. Based on the reported
clinical trials, nearly 56.6% (26%-72%) of patients would
receive 2nd-line chemotherapy regardless of the first-line
treatment [5-10]. Of those, 50% of patients were given
docetaxel ($1,942.4 per cycle), 20% gefitinib ($1,921.1 per
cycle),15% erlotinib ($2,265.5 per cycle), and 15% were
given pemetrexed ($4,383.3 per cycle) according to the
expert opinions of Chinese oncologists. Patients would
receive four median cycles of 2nd-line chemotherapy. The
costs of four 2nd-line chemotherapies were derived from a
previously published study, which estimated the cost of
each 2nd-line drug treatment regimen for Chinese patients
with NSCLC [28]. The utilization of resources related to
supportive care, such as pain/sedation intervention,
cachexia intervention, palliative radiotherapy and
Table 1 Clinical data
Parameter Values Description
and references
Weibull survival model of PFS
in the Control strategy
Scale = 0.1559; [11]
Shape = 1.045;
r2 = 0.976
Weibull survival model of OS
for supportive care
Scale = 0.04006;
Shape = 1.156; [20]
r2 = 0.9898
Weibull survival model of OS
for 2nd-line chemotherapy
Scale = 0.03897; [20]
Shape = 1.509;
r2 = 0.981
HR of PFS for the Gefitinib
strategy in patients with an
EGFR mutation
0.17 (95%
CI:0.07–0.42)
[11]
Frequency of EGFR mutations 50% (range:
8%–70%)*
[11]
Proportion of patients receiving
2nd-line chemotherapy
56.6% (range:
26%–72%)*
[5-10]
Frequency of follow-up
0–2 years Once per four
months
[26]
after 2 years Once per year [26]
Probability of SAEs in the
Gefitinib strategy
7% (range:
5.25%–8.75%)*
[11]
Probability of SAEs in the Control
strategy
3% (range:
2.25%–3.75%)*
[11]
Probability of SAEs using
platinum-based chemotherapy
80% (range:
60%–100%)*
[27]
* The range was assumed for one-way sensitivity analysis.
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records of 109 patients who received supportive care. In
addition, the current analysis also included the cost of
palliative care in end-of-life treatment, which was esti-
mated from the records of 91 patients who died from
NSCLC. Our analyses included the SAE treatment costs.
The cumulative probabilities of SAEs were obtained
from clinical trials, and we assumed that these events
occurred with the same probabilities in every cycle. Due
to the absence of cost data associated with adverse
events in maintenance therapy, the costs of SAEs were
calculated as the cumulative probabilities of the
weighted average of first-line standard strategy SAE
costs by the following formula: cost of SAEs in
platinum-based chemotherapy per cycle × cumulative
probability of SAEs in maintenance strategy / cumulative
probability of SAEs in platinum-based chemotherapy.
Because it can be a challenge for patients to afford gefiti-
nib in China, the Gefitinib Patient Assistance Program
(GPAP) supplied by the pharmaceutical producer was
introduced to make gefitinib available to eligible patients.
Currently, the GPAP requires NSCLC patients to pay forsix months of gefitinib, after which they receive donations
of gefitinib until the end of their treatment. Therefore, the
scenario analyses evaluated the importance of GPAP for
gefitinib.
The utility values of the progression free survival and
survival with disease progression were derived from previ-
ously published studies, and 0.65 and 0.47 were assigned,
respectively. The standard errors were estimated at 25%
of the mean in our sensitivity analysis [29].
Expected Cost and effectiveness(QALY and LY)
accrued for the entire Markov process is the total num-
ber of cycles spent in each health state, each multiplied
by the cost and effectiveness for that state.Sensitivity analyses
The median PFS and OS time of advanced NSCLC
would not exceed one and two years, and most of
patients would die within five years [30]. In base case
analysis, the timeframe of 1 (scenario 1), 2 (scenario 2)
and 5 (scenario 3) years was used to test the impact of
observational period on the model outputs. The influ-
ences of each parameter value in the model were exam-
ined through one-way sensitivity analyses. The results
of these analyses are presented as a tornado diagram
depicting the lower and upper values for the cost-
effectiveness ratios of the Gefitinib strategy versus the
Control strategy for each varied model input, which
are listed and illustrated in Table 1 and Table 2. A
probabilistic sensitivity analysis (PSA) was performed
to examine the uncertainty related to which strategy
has the greatest likelihood of being cost-effective by
randomly sampling the parameters from defined distri-
butions. The model used log-normal distributions for
costs and beta distributions for utility values and
probabilities or proportions with an assumed standard
deviation of 25% from the mean values when reported
data were not available. Using these distributions, one
thousand iterations of the model were conducted to
generate the total cost and QALY distributions for
each strategy. The net monetary health benefit
(NMHB) was used to indicate the economic outcome
of each strategy for any iteration. The NMHB varies
depending on the value of willingness to pay (WTP).
The current analysis used three times the per capita
GDPs of China and Shanghai City as the thresholds
according to the World Health Organization (WHO)
guidelines for cost-effectiveness analysis [31-33]. The
probability of an NMHB for each strategy can be
measured by comparing the number of achieving the
greatest NMHB across all 1000 iterations. The results
are shown as a cost-effectiveness acceptability curve
(CEAC) with varied WTP values in a range from US
$0/QALY to US $100,000/QALY.
Table 2 Base-case costs estimates ($, year 2012 values) and utilities
Parameter Median Range Description and references
Cost of EGFR genotyping per patient 507.9 381–634.9 Local charge
Cost of gefitinib per 250 mg ($) 77.8 38.9–77.8* Local charge
Cost of follow-up per unit ($) 55.6 41.7–69.4 [34]
Cost of 2nd-line chemotherapy per cycle ($) 2352.7 1921.1–4383.3 Calculation
Cost of palliative care in end-of-life treatment ($) 3664.3 21.4–48750.2 Calculation
Cost of supportive care per cycle ($) 337.5 158.7–793.7 Calculation
Cost of SAEs in platinum-based chemotherapy per cycle ($) 507.4 189.7–825.0 Calculation
Expenditures of SAEs in maintenance treatment per cycle
Cost of SAEs in Gefitinib strategy per cycle ($) Formula# Calculation
Utilities
Utility of PFS 0.65 0.26–0.87 [29]
Utility of OS 0.47 0.19–0.58 [29]
* The range was assumed for a one-way sensitivity analysis.
# Formula: Cost of SAEs in platinum-based chemotherapy per cycle × Cumulative probability of SAEs in maintenance strategy / Cumulative probability of SAEs in
platinum-based chemotherapy.
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Base-case analysis
The model results indicate that imitating gefitinib main-
tenance treatment increased the health benefits for
patients who had completed standard first-line chemo-
therapy. Increased progression free LYs appeared after 1,
2, 5 and 10 years (gained an additional 0.22, 0.45, 0.69 and
0.74 years, respectively), and LYs increased by 0.16, 0.41,
0.69 and 0.74 years, respectively. The additional QALYs
gained ranged from 0.12 at 1 year to 0.46 at 10 years
(Table 3). The increased costs of the Gefitinib strategyTable 3 Summary of the cost and outcome results in base-cas
Strategy Cost($) Progression free LYs
1 year (scenario 1)
Control 2,981.3 0.35
Gefitinib without GPAP 13,775.3 0.56
Gefitinib with GPAP 8,980.4 0.56
2 year (scenario 2)
Control 4,545.6 0.36
Gefitinib without GPAP 22,063.0 0.81
Gefitinib with GPAP 10,660.6 0.81
5 year (scenario3)
Control 4,913.2 0.36
Gefitinib without GPAP 29,705.8 1.06
Gefitinib with GPAP 11,884.7 1.06
10 year
Control 4,917.0 0.36
Gefitinib without GPAP 31,066.9 1.11
Gefitinib with GPAP 12,095.2 1.11
* Compared with Control strategy.without or with the GPAP were $10,794.00 and $5,999.10
at 1 year to $26,149.90 and $7,178.20 at 10 years, respect-
ively. The ICER for gefitinib maintenance was $57,066.40
per QALY gained and $35,260.10 per LY gained at 10
years. When the GPAP was included, the ICER decreased
to $15,664.80 per QALY gained and $9,678.90 per LY
gained.
Uncertainty analyses
The one-way sensitivity analyses showed that some
model variables had a substantial impact on the results;e analysis
Overall LYs QALYs Incremental cost per QALY*
0.51 0.30
0.67 0.42 92,968.5
0.67 0.42 51,669.9
0.57 0.33
0.97 0.60 65,514.8
0.97 0.60 22,870.0
0.57 0.33
1.26 0.76 57,788.9
1.26 0.76 16,249.9
0.57 0.33
1.31 0.79 57,066.4
1.31 0.79 15,664.8
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Regardless of the GPAP, the two most influential vari-
ables were the utility of progression free survival and the
HR of PFS for the Gefitinib strategy in patients with an
EGFR mutation. The cost of gefitinib per dose, the fre-
quency of EGFR mutations and the cost of palliative care
in end-of-life treatment had a medium impact on the
ICER. Other parameters, such as the cost, median OS
time of 2nd-line chemotherapy or supportive care, and
probability of SAEs, had little sensitivity on the model
outputs. With GPAP, model output was moderately
sensitive to the median PFS time of control strategy.
A two-way sensitivity analysis incorporating the
frequency of EGFR mutations and the cost of EGFRA. Without GPAP
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Figure 2 One-way sensitivity analyses show the lower and upper valu
Control strategy for each parameter.genotyping was performed. This analysis indicated that
gefitinib maintenance was more cost-effective in the
population with a higher rate of EGFR mutation-
positive advanced NSCLC. The ICER was sensitive to
rates from approximately 7% to 20%. A lower cost of
detecting EGFR mutations would improve the ICER
values of the Gefitinib strategy. However, the impact
was small (Figure 3).
When no GPAP was supplied, the probabilistic sensi-
tivity analysis showed a nearly zero cost-effective prob-
ability even at a threshold of $38,733.30 (Figure 4). In
the GPAP setting, when the threshold was equal to three
times the per capita GDPs of China ($16,349.10) and
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Figure 3 Two-way sensitivity analysis of the effects of the frequency of EGFR mutations and the cost of EGFR genotyping.
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respectively. Correspondingly, the acceptability curves
showed that the probability of cost-effectiveness also
increased with an increase in the willingness-to-pay
threshold, which was sensitive to the thresholds from
approximately $41,000 to $100,000 in the no-GPAP set-
ting and from approximately $9,700 to $35,000 in the
GPAP setting (Figure 5).
Discussion
Reports of a clinical benefit from gefitinib maintenance
therapy after first-line platinum-based chemotherapy in
clinical trials caused great excitement among both
oncologists and patients. However, the widespread and
long-term use of gefitinib comes with a dramatically
increased burden on health resources, which is a con-
cern for health policy decision makers. The need for a
precise economic assessment of gefitinib maintenance
use in this clinical setting is becoming urgent.
This work is the first study to address the cost-effec-
tiveness of gene-guided gefitinib maintenance treatment
after standard chemotherapy for patients with advanced
EGFR mutation-positive NSCLC. Genotyping for EGFR
mutations with the subsequent gefitinib maintenance
treatment of patients with confirmed mutations yielded
an average ICER of $57,066.40 per additional QALY gai-
ned against control strategy. This ratio is largely attribut-
able to the higher costs associated with the acquisition of
gefitinib, whereas the costs of EGFR genotyping and the0
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Figure 5 The cost-effectiveness acceptability curves showing the prob
compared to the Control strategy at different WTP thresholds in advacosts of managing progressed disease had little influence.
Finding of scenario analyses in Table 3 indicated that gefi-
tinib would be more cost-effective (ICER without GPAP,
$92,968.5/QALY at 1 year to $57,066.4/QALY at 10 year )
with the longer timeframe because the health benefit re-
lated to progression free survival yielded by gefitinib could
be more obviously displayed (incremental progression free
LYs, 2.2 at 1 year to 0.7 at 10 year; incremental overall
LYs, 0.16 at 1 year to 0.74 at 10 year; incremental QALYs,
0.12 at 1 year to 0.46 at 10 year ), especially after two
years. At one year, more patients in gefitinib arm was
still in the state of progression-free survival and more
patients in control arm had moved into progressed sur-
vival, which resulted in the gap between the incremental
progression free LYs and the incremental overall LYs in
gefitinib strategy comparing with control strategy. Peme-
trexed switch maintenance treatment has been widely
recommended for patients with advanced NSCLC. A
pharmacoeconomic analysis from a US payer and the
Swiss Health Care System perspective showed that the pe-
metrexed switch maintenance treatment resulted in an in-
cremental cost of $122,371 per additional life year gained
and $138,500 per additional QALY gained in patients with
nonsquamous cell histology [22,35]. In comparison with
pemetrexed switch maintenance treatment, gene-guided
gefitinib maintenance has a much more favorable ICER,
which is considerably contributed by the more favorable
PFS time of gefitinib than pemetrexed in patients with
EGFR mutations (16.6 months vs. 4.4 months) [8,11].60 80 100
esholds($×1,000/QALYs)
Without GPAP
With GPAP
3.3
 of Shanghai)
abilities of net benefits achieved by the Gefitinib strategy
nced NSCLC patients.
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http://www.biomedcentral.com/1471-2407/13/39These results suggest that gefitinib maintenance tailoring
for patients with EGFR mutations could deliver health
benefits at a lower cost than pemetrexed switch main-
tenance therapy. This finding comes in line with the two
recent economic studies, which provided the favorable
economic evidence to support the first-line therapy with
gefitinib for patients with EGFR mutation-positive and
traditional chemotherapy for those with EGFR mutation-
negative after mutation testing [36,37].
Although gefitinib maintenance yielded greater health
benefits, the ICER did not approach the willingness-
to-pay thresholds of $16,349.10 and $38,733.30 (3× the
per capita GDPs of China and Shanghai in 2011, re-
spectively). If the Gefitinib Patient Assistance Program
were available to Chinese patients, the Gefitinib strategy
might be a cost-effective alternative because the prob-
ability of cost-effectiveness reached nearly 51% at a
threshold of $16,349.10 (Figures 4 and 5). For local
governments in China, the per capita GDP differs
significantly among the 32 provinces. In regions with a
higher economic development level (3× the per capita
GDP > $16,349.10), local health decision makers could
consider covering gefitinib in their local supplemental
medical service.
The ability of gefitinib to prevent disease progression
in patients with EGFR mutation-positive tumors was a
major determinant of clinical and economic outcomes.
A one-way sensitivity analysis found that the most two
sensitive parameters were the HR of PFS for the Gefitinib
strategy in patients with EGFR mutations and the utility
of progression free survival regardless of the use of the
GPAP. This finding suggests that improving the quality
of life, i.e., achieving the progression free state, could
increase the cost-effectiveness of gefitinib maintenance
treatment. At the same time, in patients who have a low
risk of disease progression, such as adenocarcinoma
histology, gefitinib maintenance treatment might be
more cost-effective. The cost of gefitinib was another
influential factor. When the price of gefitinib per 250
mg decreased by 50%, the ICERs for the Gefitinib
strategy decreased to $29,493.40 and $8,792.60 per add-
itional QALY gained without or with the GPAP, respect-
ively. Although the PSA results indicated that the GPAP
leads to the cost-effective probability of the Gefitinib
strategy, approaching 51% at 3× the per capita GDP of
China, a reduction in the price of gefitinib or a more
preferential patient assistance program (i.e. pay for
shorter than six months of gefitinib, after which they
receive donations of gefitinib until the end of their treat-
ment) might be the best strategies to achieve a more
favorable ICER.
It is important to note that the current analysis did
not evaluate the cost-effectiveness of gefitinib mainte-
nance treatment for the whole cohort without EGFRgenotyping. If all patients received gefitinib mainten-
ance, the health outcome of 50% of the patients would
not have improved because no statistically significant
difference was found between the Gefitinib and Control
strategies in patients who were EGFR mutation nega-
tive [11]. The cost of gefitinib for the whole cohort in
the first 21-day cycle was nearly $1663.10, including
$831.50 expended by patients who were EGFR mutation
negative, which was higher than the cost of EGFR ge-
notyping ($507.90) for the whole cohort. Thus, it was
obvious that gefitinib maintenance without EGFR geno-
typing was not cost-effective when compared with gefi-
tinib maintenance with EGFR genotyping and would
become less cost-effective with a lower frequency of
EGFR mutations due to the increased cost of gefitinib
for patients who are EGFR mutation negative. We no-
ticed that the frequency of EGFR mutations ranged
from 8% in Caucasian patients to 30% in Asian patients.
As a result, we concluded that gene-guided gefitinib
maintenance treatment is superior to non-gene-guided
treatment [38-40].
Other limitations of the study should also be consid-
ered. First, the present model did not include other
EGFR-targeted agents used as maintenance treatments,
such as erlotinib, to assess the incremental cost-ef-
fectiveness in comparison with gefitinib because no
head-to-head trial data are currently available. Second,
we did not conduct a budget impact analysis for the
addition of gefitinib maintenance treatment on society.
The annual incidence of lung cancer in China is ap-
proximately 300,000 cases [41]. Because the PFS of
advanced NSCLC was nearly 58.9% after four cycles of
standard chemotherapy and the frequency of EGFR
mutations was 50%, gefitinib might be prescribed as a
maintenance treatment to more than 88,000 patients
each year [27]. Based on our model results, gefitinib
maintenance treatment would result in a gain of ap-
proximately 24,700 QALYs and would increase expendi-
tures by approximately $1,399 and $395 million without
and with GPAP, respectively. Third, the current analysis
incorporated PSF and OS data after cancer progression
from different trials. Although the sensitivity of the OS
data after cancer progression was little (Figure 2), the
analysis should be updated when the overall survival
of gefitinib maintenance therapy was available. Forth,
some model inputs were obtained from literature pub-
lished abroad due to a lack of Chinese data, such as the
utility values. Fifth, the sensitivity and specificity of
different genotyping facilities was not accounted. A
new economic analysis of different genotyping facilities
testing for EGFR mutations is necessary in the future.
Finally, to simplify our evaluation, we did not include
other adjuvant therapies, such as the traditional Chinese
herbals for lung cancer. However, because the results of
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http://www.biomedcentral.com/1471-2407/13/39this analysis reflected the common clinical conditions of
advanced NSCLC in China, we believe that this analysis
can serve as an important reference for health policy
decision makers.
Conclusions
In the Chinese setting, gene-guided gefitinib maintenance
treatment for patients with advanced NSCLC and EGFR
mutation-positive tumors after first-line chemotherapy is
indicated as a cost-effective chemotherapy option com-
pared to routine follow-up based on its superior PFS be-
nefit and the use of the Patient Assistance Program.
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